4//SEC Filing
ACURA PHARMACEUTICALS, INC 4
Accession 0001209191-14-014103
$ACURCIK 0000786947operating
Filed
Feb 24, 7:00 PM ET
Accepted
Feb 25, 5:10 PM ET
Size
15.4 KB
Accession
0001209191-14-014103
Insider Transaction Report
Form 4
GALEN EMPLOYEE FUND III LP
10% Owner
Transactions
- Sale
Common Stock
2014-02-21$1.95/sh−272$530→ 11,526,126 total(indirect: See FN) - Sale
Common Stock
2014-02-24$1.97/sh−43,747$86,024→ 11,482,379 total(indirect: See FN)
Galen Management, LLC
10% Owner
Transactions
- Sale
Common Stock
2014-02-21$1.95/sh−272$530→ 11,526,126 total(indirect: See FN) - Sale
Common Stock
2014-02-24$1.97/sh−43,747$86,024→ 11,482,379 total(indirect: See FN)
GALEN PARTNERS III L P
10% Owner
Transactions
- Sale
Common Stock
2014-02-21$1.95/sh−272$530→ 11,526,126 total(indirect: See FN) - Sale
Common Stock
2014-02-24$1.97/sh−43,747$86,024→ 11,482,379 total(indirect: See FN)
CLAUDIUS LLC
10% Owner
Transactions
- Sale
Common Stock
2014-02-24$1.97/sh−43,747$86,024→ 11,482,379 total(indirect: See FN) - Sale
Common Stock
2014-02-21$1.95/sh−272$530→ 11,526,126 total(indirect: See FN)
GALEN PARTNERS INTERNATIONAL III L P
10% Owner
Transactions
- Sale
Common Stock
2014-02-21$1.95/sh−272$530→ 11,526,126 total(indirect: See FN) - Sale
Common Stock
2014-02-24$1.97/sh−43,747$86,024→ 11,482,379 total(indirect: See FN)
Footnotes (5)
- [F1]The shares were sold as follows: 248 by Galen Partners III, L.P. ("Galen III"), 22 by Galen Partners International III, L.P. ("Galen International") and 2 by Galen Employee Fund III, L.P. ("Employee Fund").
- [F2]The shares are held as follows: 10,532,820 by Galen III, 949,920 by Galen International and 43,386 by Employee Fund. Claudius, L.L.C. serves as the sole General Partner of Galen III and Galen International and has sole voting and investment control over the shares held by such funds and may be deemed to beneficially own the shares held by such funds. Galen Management, L.L.C. serves as the sole General Partner of Employee Fund and has sole voting and investment control over the shares held by Employee Fund and may be deemed to beneficially own the shares held by Employee Fund. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein, except to the extent of its respective pecuniary interest therein.
- [F3]The shares were sold as follows: 39,965 by Galen III, 3,617 by Galen International and 164 by Employee Fund.
- [F4]The shares were sold at prices between $1.96 and $1.98. The Reporting Entities will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F5]The shares are held as follows: 10,492,855 by Galen III, 946,303 by Galen International and 43,222 by Employee Fund. Claudius, L.L.C. serves as the sole General Partner of Galen III and Galen International and has sole voting and investment control over the shares held by such funds and may be deemed to beneficially own the shares held by such funds. Galen Management, L.L.C. serves as the sole General Partner of Employee Fund and has sole voting and investment control over the shares held by Employee Fund and may be deemed to beneficially own the shares held by Employee Fund. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein, except to the extent of its respective pecuniary interest therein.
Documents
Issuer
ACURA PHARMACEUTICALS, INC
CIK 0000786947
Entity typeoperating
IncorporatedNY
Related Parties
1- filerCIK 0000786947
Filing Metadata
- Form type
- 4
- Filed
- Feb 24, 7:00 PM ET
- Accepted
- Feb 25, 5:10 PM ET
- Size
- 15.4 KB